<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05626569</url>
  </required_header>
  <id_info>
    <org_study_id>2022-FXY-119</org_study_id>
    <nct_id>NCT05626569</nct_id>
  </id_info>
  <brief_title>Anti-PD-1 Immunotherapy Combined With SBRT for Patients With Oligometastatic ESCC</brief_title>
  <official_title>Phase 2 Study of Anti-PD-1 Immunotherapy Combined With Stereotactic Body Radiation Therapy for Patients With Oligometastatic Esophageal Squamous Cell Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this phase II clinical trial is to explore the efficacy and safety of anti-PD1&#xD;
      combined with stereotactic body radiation therapy (SBRT) for patients with oligometastatic&#xD;
      esophageal squamous cell carcinoma. Participants will receive anti-PD1 and SBRT to the&#xD;
      metastatic lesions which are amenable to the delivery of SBRT after 4~6 cycles of systemic&#xD;
      chemotherapy and anti-PD-1.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 10, 2022</start_date>
  <completion_date type="Anticipated">July 1, 2025</completion_date>
  <primary_completion_date type="Anticipated">November 1, 2024</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>1-year progression-free survival</measure>
    <time_frame>From date of randomization until the date of death from any cause or the date of first documented disease progression whichever came first, assessed up to 12 months</time_frame>
    <description>1-year progression-free survival</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>1-year overall survival</measure>
    <time_frame>From date of randomization until the date of death from any cause or the date of last follow-up, whichever came first, assessed up to 12 months</time_frame>
    <description>1-year overall survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ORR</measure>
    <time_frame>3 months after SBRT (plus or minus 14 days)]</time_frame>
    <description>Overall response rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment-related adverse events</measure>
    <time_frame>From the start of treatment to 2 year after the completion of treatment</time_frame>
    <description>Toxicity of treatment was evaluated according to CTCAE 4.0</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Esophageal Squamous Cell Carcinoma</condition>
  <condition>Oligometastatic Disease</condition>
  <arm_group>
    <arm_group_label>PD-1 combined with SBRT for metastatic lesions</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive anti-PD1 and SBRT to the metastatic lesions which are amenable to the delivery of SBRT after 4~6 cycles of systemic chemotherapy and anti-PD-1. SBRT for the metastatic lesions shall be conducted within two months after the completion of systemic therapy. The prescription of SBRT is determined by the investigator and the BED is required to over 50Gy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PD-1 combined with SBRT</intervention_name>
    <description>Anti-PD1 monoclonal antibody combined with SBRT. The SBRT defined as the radiation prescription with single dose equal or over 4Gy and the fractions less or equal to 10 fractions. BED equal or over 50Gy is required.</description>
    <arm_group_label>PD-1 combined with SBRT for metastatic lesions</arm_group_label>
    <other_name>SBRT</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Eastern Cooperative Oncology Group performance status ≤ 2;&#xD;
&#xD;
          2. Histologically confirmed squamous cell carcinoma of the esophagus;&#xD;
&#xD;
          3. Diagnosed with stage IVB disease (according to UICC TNM version 8) with less than five&#xD;
             metastatic lesions within three organs;&#xD;
&#xD;
          4. Received 4 to 6 cycles of standard chemotherapy (fluoropyrimidine or taxane-based&#xD;
             platinum doublet chemotherapy) and anti-PD1 treatment, and no progression disease was&#xD;
             confirmed;&#xD;
&#xD;
          5. At least one metastatic lesions amenable to the delivery of SBRT;&#xD;
&#xD;
          6. Estimated life expectancy &gt;4 months;&#xD;
&#xD;
          7. The function of important organs meet the following requirements: a. white blood cell&#xD;
             count (WBC) ≥ 4.0×109/L, absolute neutrophil count (ANC) ≥ 1.5×109/L; b. platelets ≥&#xD;
             100×109/L; c. hemoglobin ≥ 9g/dL; d. serum albumin ≥ 2.8g/dL; e. total bilirubin ≤&#xD;
             1.5×ULN, ALT, AST and/or AKP ≤ 2.5×ULN; f. serum creatinine ≤ 1.5×ULN or creatinine&#xD;
             clearance rate &gt;60 mL/min;&#xD;
&#xD;
          8. Ability to understand the study and sign informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Progression was confirmed after completion of 4 to 6 cycles of standard chemotherapy&#xD;
             and anti-PD1 treatment;&#xD;
&#xD;
          2. Patients with intracranial metastasis disease at diagnosis;&#xD;
&#xD;
          3. History of thoracic irradiation;&#xD;
&#xD;
          4. Known or suspected allergy or hypersensitivity to monoclonal antibodies and the&#xD;
             chemotherapeutic drugs: Capecitabine, paclitaxel, or platinum;&#xD;
&#xD;
          5. Patients have spinal bone metastases combined with spinal cord compression;&#xD;
&#xD;
          6. A history of malignancies other than esophageal cancer before enrollment, excluding&#xD;
             non-melanoma skin cancer, in situ cervical cancer, or cured early prostate cancer;&#xD;
&#xD;
          7. Patients who cannot tolerate radiotherapy due to severe cardiac, lung, liver, or&#xD;
             kidney dysfunction, or hematopoietic disease or cachexia;&#xD;
&#xD;
          8. Inability to provide informed consent due to psychological, familial, social, and&#xD;
             other factors;&#xD;
&#xD;
          9. Female patients who are pregnant or during lactation;&#xD;
&#xD;
         10. Active autoimmune diseases, a history of autoimmune diseases (including but not&#xD;
             limited to these diseases or syndromes, such as colitis, hepatitis, hyperthyroidism),&#xD;
             a history of immunodeficiency (including a positive HIV test result), or other&#xD;
             acquired or congenital immunodeficiency diseases, a history of organ transplantation&#xD;
             or allogeneic bone marrow transplantation;&#xD;
&#xD;
         11. A history of interstitial lung disease or non-infectious pneumonia; Presence of active&#xD;
             hepatitis B (HBV DNA ≥ 2000 IU/mL or 104 copies/mL), hepatitis C (positive for&#xD;
             hepatitis C antibody, and HCV-RNA levels higher than the lower limit of the assay).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mian Xi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sun Yat-sen University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mian Xi, MD</last_name>
    <phone>02087340540</phone>
    <email>ximian@sysucc.org.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Baoqing Chen, MD</last_name>
    <phone>02087340540</phone>
    <email>chenbq@sysucc.org.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Mian Xi</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Baoqing Chen</last_name>
      <phone>02087340540</phone>
      <email>chenbq@sysucc.org.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Liu Q, Zhu Z, Chen Y, Deng J, Ai D, Liu Q, Wang S, Wu S, Chen J, Zhao K. Phase 2 Study of Stereotactic Body Radiation Therapy for Patients with Oligometastatic Esophageal Squamous Cell Carcinoma. Int J Radiat Oncol Biol Phys. 2020 Nov 1;108(3):707-715. doi: 10.1016/j.ijrobp.2020.05.003. Epub 2020 May 14.</citation>
    <PMID>32417405</PMID>
  </reference>
  <reference>
    <citation>Liu S, Luo L, Zhao L, Zhu Y, Liu H, Li Q, Cai L, Hu Y, Qiu B, Zhang L, Shen J, Yang Y, Liu M, Xi M. Induction chemotherapy followed by definitive chemoradiotherapy versus chemoradiotherapy alone in esophageal squamous cell carcinoma: a randomized phase II trial. Nat Commun. 2021 Jun 29;12(1):4014. doi: 10.1038/s41467-021-24288-1.</citation>
    <PMID>34188053</PMID>
  </reference>
  <verification_date>December 2022</verification_date>
  <study_first_submitted>November 17, 2022</study_first_submitted>
  <study_first_submitted_qc>November 22, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">November 23, 2022</study_first_posted>
  <last_update_submitted>December 18, 2022</last_update_submitted>
  <last_update_submitted_qc>December 18, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">December 20, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-sen University</investigator_affiliation>
    <investigator_full_name>Mian XI</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>esophageal cancer; oligometastases; PD-1; SBRT</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Esophageal Squamous Cell Carcinoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

